Skip to main content
. Author manuscript; available in PMC: 2013 Jun 26.
Published in final edited form as: J Thorac Oncol. 2012 Oct;7(10):1583–1593. doi: 10.1097/JTO.0b013e31826146ee

FIGURE 2.

FIGURE 2

The choice of treatment schedule influences the plasma concentrations of erlotinib. Erlotinib plasma concentration as a function of time during several dosing schedules (50 mg/d, 25 mg/d, 150 mg/d, and 1600 mg/week, and 1600 mg/week with 50 mg on remaining days.